As you will be aware, the Department for Health and Social Care has asked NICE to carry out an appraisal of blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia.
Please note that following an update from the company, this appraisal has been scheduled back into the work programme. The appraisal is now anticipated to begin in mid- September 2019.